Boron-containing small molecules as anti-inflammatory agents

• US 9,029,353 B2
• Filed: 07/30/2013
• Issued: 05/12/2015
• Est. Priority Date: 02/16/2006
• Status: Active Grant

• Current Assignee: Anacor Pharmaceuticals, Inc. (Pfizer Inc.)
• Original Assignee: Anacor Pharmaceuticals, Inc. (Pfizer Inc.)
• Inventors: Baker, Stephen J., Sanders, Virginia, Akama, Tsutomu, Bellinger-Kawahara, Carolyn, Freund, Yvonne, Maples, Kirk R., Plattner, Jacob J., Zhang, Yong-Kang, Zhou, Huchen, Hernandez, Vincent S.
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US13/954,770
• Publication Number:
  US 20130316979A1
• Time in Patent Office: 651 Days
• Field of Search: 514/64
• US Class Current: 514/64
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/12 Antidiarrhoeals
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/06 : Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 19/08 : for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 : for osteoporosis
• CPC Class Codes: A61P 21/00 : Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 : for myasthenia gravis
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 : for peripheral neuropathies
• CPC Class Codes: A61P 25/06 : Antimigraine agents
• CPC Class Codes: A61P 25/08 : Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 : for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 : Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 : Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 : Anxiolytics
• CPC Class Codes: A61P 25/24 : Antidepressants
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 : for treating abuse or dependence
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 27/06 : Antiglaucoma agents or miotics
• CPC Class Codes: A61P 27/14 : Decongestants or antiallergics
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 : Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/08 : for leprosy
• CPC Class Codes: A61P 31/12 : Antivirals
• CPC Class Codes: A61P 31/14 : for RNA viruses
• CPC Class Codes: A61P 31/16 : for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 : for HIV
• CPC Class Codes: A61P 33/02 : Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 33/06 : Antimalarials
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 39/02 : Antidotes
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 7/08 : Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/02 : Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• CPC Class Codes: A61P 9/04 : Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/08 : Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 : Antihypertensives
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: C07F 5/027 : Organoboranes and organoborohydrides
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

Claims

1. A method of treating an inflammatory-related disease in a human or an animal, said method comprising administering to the human or the animal a therapeutically effective amount of a compound having a structure selected from the group consisting of

2. The method of claim 1, further comprising administering said compound as part of a pharmaceutical formulation, said formulation further comprising a pharmaceutically acceptable excipient.

3. The method of claim 1, wherein said compound is present in a form which is a member selected from a hydrate with water, a solvate with an alcohol, an adduct with an amino compound, and an adduct with an acid.

4. The method of claim 1, wherein said compound has a structure selected from the group consisting of:

5. The method of claim 1, wherein the compound is in an amount sufficient to treat the inflammatory-related disease by inhibiting pro-inflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.

6. The method of claim 5, wherein the compound has a structure selected from the group consisting of

7. The method of claim 1, wherein the disease is a member selected from arthritis, rheumatoid arthritis, an inflammatory bowel disease, psoriasis, multiple sclerosis, a neurodegenerative disorder, congestive heart failure, stroke, aortic valve stenosis, kidney failure, lupus, pancreatitis, allergy, fibrosis, anemia, atherosclerosis, a metabolic disease, a bone disease, a cardiovascular disease, a chemotherapy/radiation related complication, diabetes type I, diabetes type II, a liver disease, a gastrointestinal disorder, an ophthalmological disease, allergic conjunctivitis, diabetic retinopathy, Sjogren'"'"'s syndrome, uveitis, a pulmonary disorder, a renal disease, dermatitis, HIV-related cachexia, cerebral malaria, ankylosing spondylitis, leprosy, anemia and fibromyalgia.

8. The method of claim 7, wherein the compound has a structure selected from the group consisting of

9. The method of claim 7, wherein the neurodegenerative disorder is a member selected from Alzheimer'"'"'s disease and Parkinson disease, the inflammatory bowel disease is a member selected from Crohn'"'"'s disease or ulcerative colitis;

the gastrointestinal complication is diarrhea;

the liver disease is a member selected from an autoimmune hepatitis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangitis and fulminant liver failure;

the gastrointestinal disorder is a member selected from celiac disease and non-specific colitis;

the pulmonary disorder is a member selected from allergic rhinitis, asthma, chronic obstructive pulmonary disease, chronic granulomatous inflammation, cystic fibrosis, and sarcoidosis;

the cardiovascular disease is a member selected from atheroscleotic cardiac disease, congestive heart failure and restenosis; and

the renal disease is a member selected from glomerulonephritis and vasculitis.

10. The method of claim 9, wherein the compound has a structure selected from the group consisting of

11. The method according to claim 1, wherein the compound is administered at a concentration sufficient to inhibit a cytokine which is a member selected from IL-1α

, β

, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12,IL-17, IL-18, IL-23,TNF-α

, LT, LIF, Oncostatin, and IFNc1α

, β

, γ

.

12. The method of claim 11, wherein the compound has a structure selected from the group consisting of

13. The method of claim 1, where the compound is administered at a concentration sufficient to stimulate expression of a cytokine which is a member selected from IL-4, IL-10, IL-11, W-13 and TGF-β

.

14. The method of claim 13, wherein the compound has a structure selected from the group consisting of

15. A method of treating an inflammatory-related disease associated with cytokine expression levels, which comprises administering to a human or an animal in need of such treatment the compound of claim 1.

16. The method of claim 15, wherein the compound has a structure selected from the group consisting of

17. The method of claim 1, wherein the compound is in an amount sufficient to treat the inflammatory-related disease by inhibiting pro-inflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.

18. The method of claim 17, wherein the compound has a structure selected from the group consisting of

19. The method of claim 1, wherein the animal is a human being.

20. A method for inhibiting the production of an inflammatory cytokine protein by cells capable of producing said inflammatory cytokine protein, said method comprising:

combining said cells with a therapeutic amount of the compound of claim 1, wherein production of said inflammatory cytokine by said cells is inhibited.

21. The method of claim 20, wherein the compound has a structure selected from the group consisting of

22. The method of claim 20, wherein said therapeutic amount is sufficient to inhibit the production of said inflammatory cytokine protein between about 50% and about 99%.

23. A method for inhibiting an inflammatory response in a human or an animal, said method comprising:

contacting said human or animal with a therapeutic amount of the compound of claim 1, wherein said inflammatory response is inhibited.

24. The method of claim 23, wherein the compound has a structure selected from the group consisting of

25. The method of claim 1, wherein the compound has a structure which is

26. The method of claim 1, wherein the compound has a structure which is

27. The method of claim 7, wherein the compound has a structure which is

28. The method of claim 7, wherein the compound has a structure which is

29. The method of claim 1, wherein the disease is a member selected from psoriasis, arthritis, dermatitis, allergic rhinitis, ankylosing spondylitis, Crohn'"'"'s disease, ulcerative colitis, chronic obstructive pulmonary disease, uveitis, sarcoidosis, Behcet'"'"'s disease, allergic conjunctivitis, dry eye disease, asthma, and actinic keratosis.

30. The method of claim 29, wherein the compound has a structure which is

31. The method of claim 29, wherein the compound has a structure which is

32. The method of claim 1, wherein the disease is dermatitis.

33. The method of claim 32, wherein the compound has a structure which is

34. The method of claim 32, wherein the compound has a structure which is

35. The method of claim 1, wherein the disease is dermatitis, and said dermatitis is contact dermatitis or atopic dermatitis or eczema.

36. The method of claim 35, wherein the compound has a structure which is

37. The method of claim 35, wherein the compound has a structure which is

38. The method of claim 1, wherein the disease is arthritis, and said arthritis is rheumatoid arthritis.

39. The method of claim 38, wherein the compound has a structure which is

40. The method of claim 38, wherein the compound has a structure which is

41. The method of claim 1, wherein the disease is arthritis, and said arthritis is psoriatic arthritis.

42. The method of claim 41, wherein the compound has a structure which is

43. The method of claim 41, wherein the compound has a structure which is

44. The method of claim 1, wherein the disease is rhinitis, and said rhinitis is allergic rhinitis.

45. The method of claim 44, wherein the compound has a structure which is

46. The method of claim 44, wherein the compound has a structure which is

47. The method of claim 1, wherein the disease is rhinitis, and said rhinitis is bronchial asthma.

48. The method of claim 47, wherein the compound has a structure which is

49. The method of claim 47, wherein the compound has a structure which is

50. A method of treating an inflammatory-related disease in a human or an animal, said method comprising administering to the human or the animal a therapeutically effective amount of a compound having the following structure

51. A method of treating an inflammatory-related disease in a human or an animal, said method comprising administering to the human or the animal a therapeutically effective amount of a compound having the following structure

52. A method of treating psoriasis, comprising administering to the human or the animal a therapeutically effective amount of a compound having the following structure

53. A method of treating psoriasis, comprising administering to the human or the animal a therapeutically effective amount of a compound having the following structure

54. A method of treating atopic dermatitis, comprising administering to the human or the animal a therapeutically effective amount of a compound having the following structure

55. A method of treating atopic dermatitis, comprising administering to the human or the animal a therapeutically effective amount of a compound having the following structure

56. A method of treating eczema, comprising administering to the human or the animal a therapeutically effective amount of a compound having the following structure

57. A method of treating eczema, comprising administering to the human or the animal a therapeutically effective amount of a compound having the following structure